<DOC>
	<DOCNO>NCT00406315</DOCNO>
	<brief_summary>The primary objective study evaluate change weight result switch quetiapine ziprasidone , subject schizophrenia schizoaffective disorder fail achieve satisfactory clinical response quetiapine due lack efficacy poor tolerability .</brief_summary>
	<brief_title>Study Evaluating The Safety , Tolerability , And Efficacy Of Switching From Quetiapine To Ziprasidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Males female , 18 55 year age , time consent . Subjects must primary diagnosis schizophrenia , subtype ( code 295.xx ) , schizoaffective disorder define DSMIVTR ( Diagnostic Statistical Manual Mental Disorders Fourth Edition ) Subjects must normal vital sign , physical examination , ECG , laboratory finding except minor deviation determine document clinically insignificant investigator subinvestigator medical doctor . Subjects unable provide inform consent Subjects meet criterion DSMIVTR Axis I ( Diagnostic Statistical Manual Mental Disorders Fourth Edition ) diagnosis schizophrenia schizoaffective disorder , include psychoactive substance abuse dependence within one year study entry Females pregnant , breast feeding , lactate screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>ziprasidone , quetiapine ( Seroquel ) switch , open label , flexible dose , schizophrenia , schizoaffective disorder</keyword>
</DOC>